- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06180278
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (N-MOmentum LT)
A Long-term, Open-label, Low-interventional Safety Study of Inebilizumab in the Treatment of NMOSD (N-MOmentum LT)
The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins and B-cell counts in participants with NMOSD who discontinue treatment. The objectives include:
- To establish the nadir in circulating immunoglobulins (Ig) during chronic treatment with inebilizumab and ascertain the time needed to ensure restoration of pre-treatment baseline serum levels of IgG and IgM after discontinuation of treatment
- To characterize B-cell counts throughout treatment with inebilizumab and after discontinuation until repletion of Immunoglobulin (Ig levels)
- To assess long-term safety of inebilizumab
- To assess other long-term effects of inebilizumab
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aims to enroll 30 participants who either participated in the open-label period (OLP) of the N-MOmentum study (CD-IA-MEDI-551-1155; NCT02200770), a global registrational study that determined the safety and efficacy of inebilizumab for treatment of NMOSD, or who are newly initiating inebilizumab treatment at the discretion of their physician at participating sites.
Acquired from Horizon in 2024.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- The Chinese University of Hong Kong, Prince of Wales Hospital
-
Contact:
- Mandy Liu
- Phone Number: +852-2697-5063
- Email: mandyliu@cuhk.edu.hk
-
Principal Investigator:
- Joseph Choi
-
Hong Kong, Hong Kong, 0000
- Recruiting
- Prince of Wales Hospital - Department of Medicine & Therapeutics
-
-
-
-
-
Szeged, Hungary, 6725
- Recruiting
- Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Neurologiai Klinika
-
Principal Investigator:
- Laszlo Vecsei
-
Contact:
- Monika Konyane Berenyi
- Phone Number: +36 -62545351
- Email: office.neur@med.u-szeged.hu
-
-
Csongrád
-
Szeged, Csongrád, Hungary, 6725
- Recruiting
- Szegedi Tudományegyetem, ÁOK, Szent-Györgyi Albert Klinikai Központ
-
-
-
-
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
Principal Investigator:
- Byoung Joon Kim
-
Contact:
- Mihee Hwang
- Phone Number: 82-2-3410-0293
- Email: mihee777.hwang@samsung.com
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
- Recruiting
- National Cancer Center - Neurology Clinic
-
Contact:
- Na Young Park
- Phone Number: 82-31-920-1683
- Email: sua177@ncc.re.kr
-
Principal Investigator:
- Ho Jin Kim
-
-
Gyeonggido [Kyonggi-do]
-
Goyang-si, Gyeonggido [Kyonggi-do], Korea, Republic of, 10408
- Recruiting
- National Cancer Center
-
-
Seoul Teugbyeolsi [Seoul-T'ukp
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
-
-
-
Slaskie
-
Katowice, Slaskie, Poland, 40-751
- Recruiting
- M.A.-Lek A.M. Maciejowscy S.C. Centrum Terapii SM
-
-
-
-
-
Khon Kaen, Thailand, 40002
- Recruiting
- Khon Kaen University, Srinagarind Hospital
-
Mueang Khon Kaen, Thailand, 40002
- Recruiting
- Khon Kaen University, Srinagarind Hospital
-
Contact:
- Montathip Saisakda
- Phone Number: +66833583162
- Email: montatip@kku.ac.th
-
Principal Investigator:
- Somsak Tiamkao
-
-
Khon Kaen
-
Mueang, Khon Kaen, Thailand, 40002
- Recruiting
- Srinagarind Hospital, Department of Medicine- Faculty of Medicine Khon Kaen University, Academic Clinical Research Office (ACRO)
-
Contact:
- Jureerat Ratanaphet, RN
- Phone Number: +66 08 618 6577
- Email: jurepr@kku.ac.th
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or above, and able to provide written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA] in the United States of America (USA), European Union [EU] Data Privacy Directive in the EU) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations.
- Have completed at least 2 years in the open-label period of the N-MOmentum study or are newly initiating inebilizumab treatment at a participating site.
- Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception as outlined in the protocol (subjects in the Czech Republic only must use 1 additional method of contraception) from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab; cessation of contraception after this point should be discussed with a responsible physician.
- Nonsterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide (subjects in the Czech Republic only must use 1 additional method of contraception) from Day 1 for 3 months after receipt of last treatment with inebilizumab.
- Sterilized males, without the appropriate post-vasectomy documentation on the absence of sperm in the ejaculate, who are sexually active with a female partner of childbearing potential must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab.
Exclusion Criteria:
- Have any condition that would place the participant at unacceptable risk of complications, interfere with evaluation of inebilizumab or confound the interpretation of participant safety or study results.
- Received rituximab or any other B-cell depleting agent after exit from N-MOmentum study, or within the last 12 months prior to screening for non N-MOmentum participants.
- Known history of allergy or reaction to any component of inebilizumab formulation or history of anaphylaxis following any biologic therapy
- Have a severe clinically significant infection, including active chronic infection such as hepatitis B
- Have active or untreated latent tuberculosis
- Have a history of progressive multifocal leukoencephalopathy (PML)
- Is severely immunocompromised state
- Have active malignancies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Participants with NMOSD exposed to inebilizumab
Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
|
Participants will have blood tests done at each scheduled visit (approximately every 6 months).
Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment at the discretion of their treating physician will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in serum Ig levels (total Ig, IgG, IgM, IgA, IgE) over time
Time Frame: Up to 42 months
|
This will be assessed via serum samples, drawn at the site and processed at a central laboratory, and analyses performed to assess change from baseline over time, as measured by each parameter in mg/dL
|
Up to 42 months
|
Change from baseline in peripheral CD20+ B-cell counts over time
Time Frame: Up to 42 months
|
This will be assessed via serum samples, drawn at the site and processed at a central laboratory, and analyses performed to assess change from baseline over time, as measured by each parameter in cells/mL
|
Up to 42 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in hematology over time
Time Frame: Up to 42 months
|
The lab parameters being assessed as part of the hematology analyses include the following: platelet count, red blood cell count, other indices of red blood cells, including MCV (mean corpuscle volume), MCH (mean corpuscle hemoglobin), % reticulocyte count, and morphology (shape); white blood count with differential, including neutrophil count, Lymphocyte count, monocyte count, eosinophils, and basophils; hemoglobin and hematocrit.
|
Up to 42 months
|
Change from baseline in clinical chemistry over time
Time Frame: Up to 42 months
|
The lab parameters being assessed as part of clinical chemistry include blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase.
|
Up to 42 months
|
Incidence of serious infections
Time Frame: Up to 42 months
|
Up to 42 months
|
|
Incidence of viral reactivation
Time Frame: Up to 42 months
|
Up to 42 months
|
|
Incidence of progressive multifocal leukoencephalopathy (PML)
Time Frame: Up to 42 months
|
Up to 42 months
|
|
Incidence of other opportunistic infections
Time Frame: Up to 42 months
|
Up to 42 months
|
|
Incidence of malignancies
Time Frame: Up to 42 months
|
Up to 42 months
|
|
Incidence of infusion reactions
Time Frame: Up to 42 months
|
Up to 42 months
|
|
Number of protocol-defined NMOSD attacks
Time Frame: Up to 42 months
|
Up to 42 months
|
|
Percentage of protocol-defined NMOSD attacks
Time Frame: Up to 42 months
|
Up to 42 months
|
|
Incidence of Anti-drug antibody (ADA) directed against Inebilizumab status and titers
Time Frame: Up to 42 months
|
Up to 42 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HZNP-UPL-401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromyelitis Optica Spectrum Disorder
-
Jagannadha R AvasaralaTerminatedMultiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder Attack | Neuromyelitis Optica Spectrum Disorder Relapse | Neuromyelitis Optica Spectrum Disorder ProgressionUnited States
-
Tianjin Medical University General HospitalWithdrawnNeuromyelitis Optica Spectrum Disorder RelapseChina
-
Feng JinzhouNot yet recruitingNeuromyelitis Optica Spectrum Disorders
-
BiocadRecruitingNeuromyelitis Optica Spectrum DisordersRussian Federation
-
First Affiliated Hospital of Fujian Medical UniversityThird Affiliated Hospital, Sun Yat-Sen University; MyBiotech Co. Ltd, ChinaCompletedNeuromyelitis Optica Spectrum DisordersChina
-
Tianjin Medical University General HospitalCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum DisordersChina
-
MedImmune LLCCompletedNeuromyelitis Optica and Neuromyelitis Optica Spectrum DisordersUnited States, Czechia, Thailand, Germany, Korea, Republic of, Israel, New Zealand, Spain, Taiwan, Japan, Turkey, Hungary, Bulgaria, Mexico, Russian Federation, Colombia, Peru, Poland, Estonia, South Africa, Canada, Australia, Hong... and more
-
Fu-Dong ShiCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum Disorders | Devic's DiseaseChina
-
Shanghai Jiaolian Drug Research and Development...Shanghai Pharmaceuticals Holding Co., LtdNot yet recruitingNeuromyelitis Optica Spectrum DisordersChina
-
Reistone Biopharma Company LimitedCompletedNeuromyelitis Optica Spectrum DisordersChina
Clinical Trials on Blood tests
-
University of Colorado, DenverTerminatedVenous ThromboembolismUnited States
-
The Netherlands Cancer InstituteBayerCompletedBone Metastases | Prostate Cancer MetastaticNetherlands
-
Centre Hospitalier Universitaire, AmiensCompletedCardiovascular AbnormalitiesFrance
-
Calimmune, Inc.Active, not recruitingHIV-1 Infection | Receipt of Cal-1 Modified Hematopoietic Cellular ProductsUnited States
-
HaEmek Medical Center, IsraelCompleted
-
University of SussexUniversity of OxfordRecruiting
-
Cwm Taf University Health Board (NHS)Cardiff University; Imperial College London; University of OxfordCompletedDiabetes Mellitus, Type 1 | SARS-CoV2 InfectionUnited Kingdom
-
Aga Khan UniversityCompletedOrthopedic Disorder
-
Carmel Medical CenterCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Alaunos Therapeutics; National Center for Research...RecruitingRetroviridae Infections | CancerUnited States